Cases & Deals

UCB S.A. completes €3 billion EMTN Programme

Clients UCB S.A.

Jones Day advised UCB S.A. in connection with the set-up of their €3 billion EMTN Programme for issuance of notes. UCB S.A. is a global biopharmaceutical company, headquartered in Brussels (Belgium) and listed on Euronext Brussels (part of the Bel 20 index). The UCB Group develops and markets human pharmaceutical products for the treatment of severe central nervous system (CNS) and immunology disorders.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.